DOCSLIB.ORG

Encoded on Chromosome 6P21.33 in Human Breast Cancers Revealed by Transcrip- Tome Analysis Yan A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Encoded on Chromosome 6P21.33 in Human Breast Cancers Revealed by Transcrip- Tome Analysis Yan A Journal of Cancer 2010, 1 38 Journal of Cancer 2010; 1:38-50 © Ivyspring International Publisher. All rights reserved Research Paper Undetectable and Decreased Expression of KIAA1949 (Phostensin) Encoded on Chromosome 6p21.33 in Human Breast Cancers Revealed by Transcrip- tome Analysis Yan A. Su1 , Jun Yang1, Lian Tao1, and Hein Nguyen1, and Ping He2 1. GenProMarkers Inc., Rockville, Maryland 20850, USA; 2. Division of Hematology, Center for Biological Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA Corresponding author: Yan A. Su, MD, PhD, GenProMarkers Inc., 9700 Great Seneca Highway, Suite 182, Rockville, Maryland 20850. Phone: (301) 326-6523; FAX: (240) 453-6208; Email:[email protected] Published: 2010.06.21 Abstract Cytogenetic aberration and loss of heterozygosity (LOH) are documented on chromosome 6 in many cancers and the introduction of a neo-tagged chromosome 6 into breast cancer cell lines mediates suppression of tumorigenicity. In this study, we described the identification of KIAA1949 (phostensin) as a putative tumor suppressor gene. Our microarray analysis screened 25,985 cDNAs between a tumorigenic and metastatic breast cancer cell line MDA-MB-231 and the chromosome 6-mediated suppressed, non-tumorigenic and non-metastatic derivative cell line MDA/H6, resulting in the identification of 651 differentially expressed genes. Using customized microarrays containing these 651 cDNAs and 117 con- trols, we identified 200 frequently dysregulated genes in 10 breast cancer cell lines and 5 tumor tissues using MDA/H6 as reference. Our bioinformatics analysis revealed that chro- mosome 6 encodes 25 of these 200 genes, with 4 downregulation and 21 upergulation. Northern analysis validated microarray results and was used to detect the size and number of RNA species of 2 downregulated (KIAA1949, PTK7) and 2 upregulated (SFRS3, HMGN3) genes in the cell lines. Particularly, the KIAA1949 gene at 6p21.33, a band region with the frequent cytogenetic aberration and LOH encodes 4 poly(A)-RNA species (4.6-, 4-, 3- and 1.5-kb) in multiple normal and breast cancer samples. Microarray analysis revealed KIAA1949 downregulation in 86.7% (n=15) of breast cancer cell lines and tumor tissues. Northern analysis demonstrated undetectable and decreased expression of KIAA1949 in 100% (n=10) of breast cancer cell lines. Taken together, these results strongly suggest KIAA1949 is a novel candidate breast cancer suppressor gene. Key words: Breast cancer, MDA-MB-231, Microarray, Tumor suppressor gene, Phostensin, KIAA1949 Introduction Cytogenetic and loss of heterozygocity (LOH) primary breast tumor tissue (n=72) were reported on studies document frequent genetic alterations on the short arm of chromosome 6 (6p) using 13 micro- chromosome 6 in many types of human cancers in- satellite markers at 6p21 (1). On the long arm of cluding breast cancer and malignant melanoma. In chromosome 6 (6q), five distinct regions of allelic im- human breast cancer, 18-57% deletion frequencies in balance or LOH were observed in breast cancer tumor http://www.jcancer.org Journal of Cancer 2010, 1 39 tissues (2-5) and cell lines (6;7). Functionally, the mi- (phostensin) using both genome-wide microarrays of crocell-mediated introduction of a neo-tagged chro- 25,985 cDNA probes and customized microarrays of mosome 6 resulted in the suppression of transformed, 651 genes and 117 controls. The genome-wide micro- tumorigenic, and/or metastatic characteristics of arrays were used to screen differentially expressed breast cancer cell lines MCF7(8), MDA-MB-231 (8), genes between the tumorigenic and metastatic breast and CAL51 (9), and of the malignant melanoma cell cancer cell line MDA-MB-231 and the chromosome line UACC903 (10). The structural and functional 6-mediated suppressed non-tumorigenic and evidence strongly suggest the presence of chromo- non-metastatic derivative cell line MDA/H6. The some 6-encoded tumor suppressor genes that have yet customized cDNA microarray contained double sets to be identified. of 651 genes and 117 controls per glass slide and was Our study of malignant melanoma using human used to analyze expression profiles in 10 breast cancer chromosome 6-mediated suppressed melanoma cell cell lines and 5 primary breast tumor specimens with line UACC903(+6) (10) led to the identification of MDA/H6 as a reference. Microarray analysis identi- chromosome 6-encoded connexin 43 (Cx43, or gap fied 200 frequently dysregulated genes in these breast junction protein, alpha 1, 43kDa [GJA1], 6q21-q23.2) cancer samples. Out of the 25 genes that are known to as a melanoma suppressor gene (11), the transfection be encoded by chromosome 6, four were downregu- and overexpression of Cx43 cDNA in breast cancer lated but 21 were upergulated. Northern analysis va- cell line MDA-MB-231 by other investigators sup- lidated the microarray results. The KIAA1949 gene is pressed the xenograft tumor growth in athymic nude known at 6p21.33, a band region with the frequent mice (12). Cx43 may be only one of several candidate cytogenetic aberration and LOH. Our Northern anal- breast cancer suppressor genes encoded by chromo- ysis on KIAA1949 detected four poly(A)-RNA bands some 6. Others include pleiomorphic adenoma (4.6-, 4-, 3- and 1.5-kb) in multiple normal and breast gene-like 1 (PLAGL1 or Zac1/Lot1, 6q24-q25) (13), cancer samples. Microarray analysis revealed the Parkinson disease (autosomal recessive, juvenile) 2 downregulation of KIAA1949 in 86.7% (n=15) of (PARK2, 6q25.2-q27) (14), and SAM and SH3 domain breast cancer cell lines and tumor tissues. Northern containing 1 (SASH1, 6q24.3) (15). Because human analysis demonstrated 100% (n=10) downregulation breast cancers are extremely heterogeneous in bio- in the cell lines. Taken together, these results strongly logical behavior and clinical outcomes, the pheno- suggest that KIAA1949 is a novel candidate breast typic complexity may be due to the broad differences cancer suppressor gene. in gene expression that are determined by genetic and epigenetic alterations accumulated during the cancer development and by the gene-environment interac- Materials and Methods tions. In addition, none of above candidate tumor Cell lines, tumor tissues, and cell culture con- suppressor genes can fully explain chromosome ditions: Table 1 list 11 breast cancer cell lines and 5 6-mediated suppression of tumorigenicity in breast tumor tissues used in this study. Ten breast cancer cell cancer cell lines MCF7 (8), MDA-MB-231 (8) and lines were purchased from American Type Culture CAL51 (9). It is conceivable that direct comparison of Collection (www.atcc.org). The MDA/H6 cell line (8) gene expression profile between a breast cancer cell was generously provided by Dr. Negrini. Cells were line and its chromosome 6-mediated suppressed de- cultured in DMEM medium with L-glutamine sup- rivative cell line may lead to the identification of a plemented with 10% fetal bovine serum. G418 (800 putative breast cancer suppressor gene. μg/ml) was added to MDA/H6 cell culture to select The DNA microarray technology (16) has facili- for the neo-tagged chromosome 6. 100 U penicillin G tated the identification of expression profiles and as- sodium and 100 µg streptomycin sulfate were added sociation of abnormal patterns to hereditary breast into each milliliter of all cell culture media as antibio- cancer (17), sporadic breast cancer (18;19), and clinical tics. Breast cancer tissue samples with pathological outcomes (20;21). Combined with PCR subtraction, reports were purchased from the Lombardi Cancer DNA microarrays were also used for rapid isolation Center Histopathology/Tissue Core, Georgetown of differentially expressed genes in breast cancers University Medical Center. The patients’ identifica- (22;23). Using cDNA microarrays, we had successfully tions of all tissue samples had been removed by the identified the chromosome 6-encoded tumor sup- core facility personnel before the PI received the pressor gene Cx43 (11). In this study, we describe the samples. All media, serum, and antibiotics were ob- identification of another chromosome 6-encoded tained from GIBCO BRL (Gaithersburg, MD). novel candidate tumor suppressor gene KIAA1949 http://www.jcancer.org Journal of Cancer 2010, 1 40 Table 1. Human Breast Cancer Cell Lines and Tumor Tissues Name Symbol Original Clinical Diagnosis Source MDA-MB-231 MB231 Adenocarcinoma ATCC* MDA/H6 MDA/H6 Non-tumorigenic Dr. Negrini (8) MDA-MB-134 MB134 Carcinoma ATCC MDA-MB-157 MB157 Carcinoma ATCC MDA-MB-436 MB436 Adenocarcinoma ATCC MDA-MB-453 MB453 Carcinoma ATCC MDA-MB-468 MB468 Adenocarcinoma ATCC BT-20 BT20 Adenocarcinoma ATCC BT-474 BT474 Ductal carcinoma ATCC BT-549 BT549 Ductal carcinoma ATCC ZR75-1 ZR751 Ductal carcinoma ATCC Breast cancer tissue 1 BCTis-1 Poorly differentiated invasive ductal carcinoma LCC* Breast cancer tissue 2 BCTis-2 Poorly differentiated infiltrating ductal carcinoma LCC Breast cancer tissue 3 BCTis-3 Poorly differentiated infiltrating carcinoma LCC Breast cancer tissue 4 BCTis-4 Poorly differentiated infiltrating ductal carcinoma LCC Breast cancer tissue 5 BCTis-5 Poorly differentiated infiltrating ductal carcinoma LCC * ATCC: American Type Culture Collection; LCC: Lombardi Cancer Center Histology Facility. Tumorigenicity test. The test was performed by Genetics) with 5-µl Poly(dA) (POLYA.GF, Research the standard methods in the IACUC approved animal Genetics) and 5-µl Cot-1 DNA (15279-011, Life Tech- protocol and core facility. Briefly, 0.1 ml of 5 x 107 cells nologies) at 42°C for 2 to 4 hours. per ml were inoculated in subcutaneous fat pad at one The first strand cDNA was labeled as follows. site of flank of female athymic nude mice at age of 4 Total RNA (0.8μg) was suspended to 8-μl Rnase-free weeks. Three mice per cell line were tested. The mice water. Two μl of 1μg/μl 10-20 mer of Oligo-(dT) were subject to euthanasia when a tumor reaches 20 (POLYT.GF, Research Genetics) was added to the mm in diameters.
Load more

Recommended publications
  • Lupus-Associated Endogenous Retroviral LTR Polymorphism and Epigenetic Imprinting Promote HRES-1/Rab4 Expression and Mtor Activation
    Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/Rab4 expression and mTOR activation Aparna Godavarthy, … , Katalin Banki, Andras Perl JCI Insight. 2019. https://doi.org/10.1172/jci.insight.134010. Research In-Press Preview Immunology Graphical abstract Find the latest version: https://jci.me/134010/pdf LUPUS-ASSOCIATED ENDOGENOUS RETROVIRAL LTR POLYMORPHISM AND EPIGENETIC IMPRINTING PROMOTE HRES-1/RAB4 EXPRESSION AND MTOR ACTIVATION Aparna Godavarthy*1, Ryan Kelly*1, John Jimah1, Miguel Beckford1, Tiffany Caza1,2, David Fernandez1,2, Nick Huang1,3, Manuel Duarte1,2, Joshua Lewis1,2, Hind J. Fadel4, Eric M. Poeschla4, Katalin Banki5, and Andras Perl1,2,3 * These authors contributed equally to the study. 1, Division of Rheumatology, Department of Medicine; 2, Department of Microbiology and Immunology; 3, Department of Biochemistry and Molecular Biology, and 5, Department of Pathology, State University of New York, Upstate Medical University, College of Medicine, 750 East Adams Street, Syracuse, New York 13210; 4, Department of Molecular Medicine; Mayo Clinic College of Medicine, 200 First Street SW, Rochester 55905, USA; Correspondence: Andras Perl, M.D., Ph.D. , State University of New York, College of Medicine, 750 East Adams Street, Syracuse, New York 13210; Phone: (315) 464-4194; Fax: (315) 464- 4176; E-mail: [email protected] Key Words: Systemic Lupus Erythematosus, T Cells, HRES-1/Rab4. mTOR, Autoimmunity The authors have declared that no conflict of interest exists. Supplementary Materials include Supplemental Methods and Supplementary Figures S1-S26. 1 ABSTRACT Overexpression and long terminal repeat (LTR) polymorphism of the HRES-1/Rab4 human endogenous retrovirus locus have been associated with T-cell activation and disease manifestations in systemic lupus erythematosus (SLE).
    [Show full text]
  • Topoisomerase 1 Suppresses Replication Stress and Genomic Instability by Preventing Interference Between Replication and Transcription
    Topoisomerase 1 suppresses replication stress and genomic instability by preventing interference between replication and transcription. Sandie Tuduri, Laure Crabbé, Chiara Conti, Hélène Tourrière, Heidi Holtgreve-Grez, Anna Jauch, Véronique Pantesco, John de Vos, Aubin Thomas, Charles Theillet, et al. To cite this version: Sandie Tuduri, Laure Crabbé, Chiara Conti, Hélène Tourrière, Heidi Holtgreve-Grez, et al.. Topoi- somerase 1 suppresses replication stress and genomic instability by preventing interference between replication and transcription.. Nature Cell Biology, Nature Publishing Group, 2009, 11 (11), pp.1315- 1324. 10.1038/ncb1984. hal-00430775 HAL Id: hal-00430775 https://hal.archives-ouvertes.fr/hal-00430775 Submitted on 14 Jun 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription Sandie Tuduri 1,2, Laure Crabbé 1, Chiara Conti 3, Hélène Tourrière 1, Heidi Holtgreve-Grez 4, Anna Jauch 4, Véronique Pantesco 5, John De Vos 5, Aubin
    [Show full text]
  • Efficacy and Mechanistic Evaluation of Tic10, a Novel Antitumor Agent
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2012 Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent Joshua Edward Allen University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Oncology Commons Recommended Citation Allen, Joshua Edward, "Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent" (2012). Publicly Accessible Penn Dissertations. 488. https://repository.upenn.edu/edissertations/488 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/488 For more information, please contact [email protected]. Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent Abstract TNF-related apoptosis-inducing ligand (TRAIL; Apo2L) is an endogenous protein that selectively induces apoptosis in cancer cells and is a critical effector in the immune surveillance of cancer. Recombinant TRAIL and TRAIL-agonist antibodies are in clinical trials for the treatment of solid malignancies due to the cancer-specific cytotoxicity of TRAIL. Recombinant TRAIL has a short serum half-life and both recombinant TRAIL and TRAIL receptor agonist antibodies have a limited capacity to perfuse to tissue compartments such as the brain, limiting their efficacy in certain malignancies. To overcome such limitations, we searched for small molecules capable of inducing the TRAIL gene using a high throughput luciferase reporter gene assay. We selected TRAIL-inducing compound 10 (TIC10) for further study based on its induction of TRAIL at the cell surface and its promising therapeutic index. TIC10 is a potent, stable, and orally active antitumor agent that crosses the blood-brain barrier and transcriptionally induces TRAIL and TRAIL-mediated cell death in a p53-independent manner.
    [Show full text]
  • SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression
    Published OnlineFirst August 20, 2019; DOI: 10.1158/0008-5472.CAN-18-3965 Cancer Molecular Cell Biology Research SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression Norihiko Kawamura1,2, Keisuke Nimura1, Kotaro Saga1, Airi Ishibashi1, Koji Kitamura1,3, Hiromichi Nagano1, Yusuke Yoshikawa4, Kyoso Ishida1,5, Norio Nonomura2, Mitsuhiro Arisawa4, Jun Luo6, and Yasufumi Kaneda1 Abstract Androgen receptor splice variant-7 (AR-V7) is a General RNA splicing SF3B2 complex-mediated alternative RNA splicing constitutively active AR variant implicated in U2 castration-resistant prostate cancers. Here, we show U2 snRNA that the RNA splicing factor SF3B2, identified by 3’ 3’ in silico and CRISPR/Cas9 analyses, is a critical 5’ 3’ splice site 5’ SF3B7 AR-V7 5’ A U2AF2 AGA Exon ? determinant of expression and is correlated SF3B6(p14) SF3B4 SF3B1 SF3B4 SF3B1 with aggressive cancer phenotypes. Transcriptome SF3B5 SF3B2 SF3B3 SF3B2 SF3B3 and PAR-CLIP analyses revealed that SF3B2 con- SF3A3 SF3B2 complex SF3A3 SF3A1 SF3A1 SF3b complex trols the splicing of target genes, including AR, to AR pre-mRNA drive aggressive phenotypes. SF3B2-mediated CE3 aggressive phenotypes in vivo were reversed by AR-V7 mRNA AR mRNA AR-V7 knockout. Pladienolide B, an inhibitor of CE3 a splicing modulator of the SF3b complex, sup- Drive malignancy pressed the growth of tumors addicted to high While the SF3b complex is critical for general RNA splicing, SF3B2 promotes inclusion of the target exon through recognizing a specific RNA motif. SF3B2 expression. These findings support the idea © 2019 American Association for Cancer Research that alteration of the splicing pattern by high SF3B2 expression is one mechanism underlying prostate cancer progression and therapeutic resistance.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplementary Files for Understanding the Functional Impact of Copy Number Alterations in Breast Cancers Using a Network Modeling Approach
    Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is © The Royal Society of Chemistry 2016 Supplementary files for Understanding the functional impact of copy number alterations in breast cancers using a network modeling approach Sriganesh Srihari1#, Murugan Kalimutho2#, Samir Lal3, Jitin Singla4, Dhaval Patel4, Peter T. Simpson3,5, Kum Kum Khanna2 and Mark A. Ragan1* 1Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia 2 QIMR-Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia 3 The University of Queensland, UQ Centre for Clinical Research, Brisbane, QLD 4029, Australia 4 Indian Institute of Technology Roorkee, Roorkee, Uttarakhand 247667, India 5 The University of Queensland, School of Medicine, Brisbane, QLD 4006, Australia Supplementary website: http://bioinformatics.org.au/tools-data/ under NetStrat Section 4.1 of main text (Materials and Methods) Choosing cut-off A pair of genes (proteins) could be co-expressed due to a number of reasons – for example, by being co- regulated by the same transcription factor or due to co-functioning in a complex via direct interactions. To identify trans-associated genes we are only interested in gene pairs (i.e. interactions in the network) whose co- expression associates with the CNA of one or both genes. In Equation 2 (main manuscript), since we compute the weighted sum of CNAs, those gene pairs which do not exhibit any CNAs (zero or low CNAs) would be assigned zero or low weights and hence will not be accounted for. In addition, we would also like to discount gene pairs from the network that show low co-expression values, by using an cut-off on the co-expression.
    [Show full text]
  • Transcriptional Control of Tissue-Resident Memory T Cell Generation
    Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Filip Cvetkovski All rights reserved ABSTRACT Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Tissue-resident memory T cells (TRM) are a non-circulating subset of memory that are maintained at sites of pathogen entry and mediate optimal protection against reinfection. Lung TRM can be generated in response to respiratory infection or vaccination, however, the molecular pathways involved in CD4+TRM establishment have not been defined. Here, we performed transcriptional profiling of influenza-specific lung CD4+TRM following influenza infection to identify pathways implicated in CD4+TRM generation and homeostasis. Lung CD4+TRM displayed a unique transcriptional profile distinct from spleen memory, including up-regulation of a gene network induced by the transcription factor IRF4, a known regulator of effector T cell differentiation. In addition, the gene expression profile of lung CD4+TRM was enriched in gene sets previously described in tissue-resident regulatory T cells. Up-regulation of immunomodulatory molecules such as CTLA-4, PD-1, and ICOS, suggested a potential regulatory role for CD4+TRM in tissues. Using loss-of-function genetic experiments in mice, we demonstrate that IRF4 is required for the generation of lung-localized pathogen-specific effector CD4+T cells during acute influenza infection. Influenza-specific IRF4−/− T cells failed to fully express CD44, and maintained high levels of CD62L compared to wild type, suggesting a defect in complete differentiation into lung-tropic effector T cells.
    [Show full text]
  • Hepatitis C Virus As a Unique Human Model Disease to Define
    viruses Review Hepatitis C Virus as a Unique Human Model Disease to Define Differences in the Transcriptional Landscape of T Cells in Acute versus Chronic Infection David Wolski and Georg M. Lauer * Liver Center at the Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA * Correspondence: [email protected]; Tel.: +1-617-724-7515 Received: 27 June 2019; Accepted: 23 July 2019; Published: 26 July 2019 Abstract: The hepatitis C virus is unique among chronic viral infections in that an acute outcome with complete viral elimination is observed in a minority of infected patients. This unique feature allows direct comparison of successful immune responses with those that fail in the setting of the same human infection. Here we review how this scenario can be used to achieve better understanding of transcriptional regulation of T-cell differentiation. Specifically, we discuss results from a study comparing transcriptional profiles of hepatitis C virus (HCV)-specific CD8 T-cells during early HCV infection between patients that do and do not control and eliminate HCV. Identification of early gene expression differences in key T-cell differentiation molecules as well as clearly distinct transcriptional networks related to cell metabolism and nucleosomal regulation reveal novel insights into the development of exhausted and memory T-cells. With additional transcriptional studies of HCV-specific CD4 and CD8 T-cells in different stages of infection currently underway, we expect HCV infection to become a valuable model disease to study human immunity to viruses. Keywords: viral hepatitis; hepatitis C virus; T cells; transcriptional regulation; transcription factors; metabolism; nucleosome 1.
    [Show full text]
  • Noelia Díaz Blanco
    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
    [Show full text]
  • Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin
    Research Article Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Alison Maloney,1 Paul A. Clarke,1 Soren Naaby-Hansen,3,4 Rob Stein,3,5 Jens-Oliver Koopman,3,4 Akunna Akpan,3,4 Alice Yang,3,4 Marketa Zvelebil,3,4 Rainer Cramer,3,4 Lindsay Stimson,1 Wynne Aherne,1 Udai Banerji,1,2 Ian Judson,1,2 Swee Sharp,1 Marissa Powers,1 Emmanuel deBilly,1 Joanne Salmons,1 Michael Walton,1 Al Burlingame,3,4 Michael Waterfield,3,4 and Paul Workman1 1Haddow Laboratories, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 2Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 3Ludwig Institute for Cancer Research and Departments of 4Biochemistry and Molecular Biology and 5Oncology, University College London, London, United Kingdom Abstract anticancer agents and provide a means of obtaining a detailed The promising antitumor activity of 17-allylamino-17-deme- molecular signature of drug action (1, 2). In addition, these thoxygeldanamycin (17AAG) results from inhibition of the methods may identify pharmacodynamic markers that can be used molecular chaperone heat shock protein 90(HSP90)and to evaluate drugs in clinical trials. Gene expression microarrays are subsequent degradation of multiple oncogenic client proteins. increasingly used to investigate the molecular responses to cancer Gene expression microarray and proteomic analysis were used drugs in tumor cells (1). Although valuable, analysis of gene to profile molecular changes in the A2780human ovarian expression at the mRNA level alone cannot adequately predict cancer cell line treated with 17AAG.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Blood-Based Molecular Biomarker Signatures in Alzheimer's
    bioRxiv preprint doi: https://doi.org/10.1101/481879; this version posted December 31, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Article Blood-based molecular biomarker signatures in Alzheimer’s disease: insights from systems biomedicine perspective Tania Islam 1,#, Md. Rezanur Rahman 2,#,*, Md. Shahjaman3, Toyfiquz Zaman2, Md. Rezaul Karim2, Julian M.W. Quinn4, R.M. Damian Holsinger5,6, and Mohammad Ali Moni 6,* 1Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia, Bangladesh; [email protected](T.I.). 2 Department of Biochemistry and Biotechnology, School of Biomedical Science, Khwaja Yunus Ali University, Sirajgonj, Bangladesh; [email protected](M.R.R.). 3 Department of Statistics, Begum Rokeya University, Rangpur, Bangladesh; [email protected] (M.S.). 4 Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia;[email protected](J.W.W.Q.). 5 Laboratory of Molecular Neuroscience and Dementia, Brain and Mind Centre, The University of Sydney, Camperdown, NSW, Australia; [email protected] (R.M.D.H.). 6 Discipline of Biomedical Science, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia; [email protected] (M.A.M.). #These two authors have made an equal contribution and hold joint first authorship for this work. * Correspondence: [email protected] (M.R.R.) or [email protected] (M.A.M.). Abstract: Background and objectives: Alzheimer’s disease (AD) is the progressive neurodegenerative disease characterized by dementia, but no peripheral biomarkers available yet that can detect the AD.
    [Show full text]